Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Caribou Biosciences, Inc. CRBU
$4.15
-$0.22 (-5.25%)
На 18:04, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
271864170.00000000
-
week52high
13.19
-
week52low
4.05
-
Revenue
13851000
-
P/E TTM
-3
-
Beta
0.00000000
-
EPS
-1.55000000
-
Last Dividend
0.00000000
-
Next Earnings Date
08 мая 2023 г. в 04:00
Описание компании
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy for the treatment of relapsed or refractory multiple myeloma. The company also develops CB-012, an allogeneic anti-CD371 CAR-T cell therapy for the treatment of relapsed or refractory acute myeloid leukemia; and CB-020, an allogeneic CAR-NK cell therapy for the treatment of solid tumors. It has collaboration with AbbVie Manufacturing Management Unlimited Company to develop CAR-T cell therapies. The company was incorporated in 2011 and is headquartered in Berkeley, California.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Citigroup | Buy | Buy | 29 авг 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 18 авг 2022 г. |
| RBC Capital | Outperform | Outperform | 10 авг 2022 г. |
| Citigroup | Buy | Buy | 13 мая 2022 г. |
| SVB Leerink | Outperform | Outperform | 12 мая 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Rizvi Syed Ali-aamir | D | 59373 | 5627 | 19 янв 2023 г. |
| Kanner Steven | D | 52200 | 21401 | 02 дек 2022 г. |
| Kanner Steven | A | 323460 | 21401 | 02 дек 2022 г. |
| Fischesser Ryan | D | 15337 | 2839 | 06 окт 2022 г. |
| Fischesser Ryan | D | 1704 | 2839 | 06 окт 2022 г. |
| Fischesser Ryan | A | 116044 | 2839 | 06 окт 2022 г. |
| Fischesser Ryan | A | 113205 | 2839 | 06 окт 2022 г. |
| Fischesser Ryan | D | 110366 | 10000 | 06 окт 2022 г. |
| MCCLUNG BARBARA G | D | 47318 | 27518 | 15 сент 2022 г. |
| MCCLUNG BARBARA G | D | 0 | 77 | 15 сент 2022 г. |
Новостная лента
Caribou: Potential To Improve Response Duration With Higher Dose Level
Seeking Alpha
24 янв 2023 г. в 07:12
Proof of concept established from the phase 1 ANTLER study in using Dose level 1 of CB-010 for the treatment of patients with relapsed/refractory B-cell NHL. Additional results from the phase 1 ANTLER study using CB-010 for the treatment of patients with relapsed/refractory B-cell NHL expected in 2023.
Caribou Biosciences to Present at 41st Annual J.P. Morgan Healthcare Conference
GlobeNewsWire
03 янв 2023 г. в 16:05
BERKELEY, Calif., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel Haurwitz, Ph.D., Caribou's president and chief executive officer, is scheduled to present a corporate update at the 41st Annual J.P. Morgan Healthcare Conference on Thursday, January 12, 2023 at 11:15 am PST.
Caribou Biosciences, Inc. (CRBU) Reports Q3 Loss, Lags Revenue Estimates
Zacks Investment Research
08 ноя 2022 г. в 18:48
Caribou Biosciences, Inc. (CRBU) delivered earnings and revenue surprises of 8.33% and 8.88%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Tradeweb Exchange-Traded Funds Update - September 2022
Seeking Alpha
14 окт 2022 г. в 13:17
Trading activity on the Tradeweb European ETF marketplace amounted to EUR 49.7 billion in September. Total consolidated U.S. ETF notional value traded in September 2022 reached USD 51 billion.
Caribou Biosciences: Strong Momentum Possible If Higher Dose Shows Durability
Seeking Alpha
12 окт 2022 г. в 07:18
Caribou Biosciences' early data was good, but not that durable. However, this was the lowest dose cohort, and safety was manageable.